Free Newsletter
BMS lowers IPO target to $600M
Free newsletter via e-mail
Tools
In what analysts see as a test of the paltry IPO market, Bristol-Myers Squibb will sell off part of its Mead Johnson subsidiary for $21 to $24 per share, hoping to bring in $600 million. That's a lot less than it originally expected to raise from Mead Johnson: $1 billion. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: